BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
about
Somatic DNA mutation analysis in targeted therapy of solid tumoursPathways and therapeutic targets in melanomaBeyond BRAF: where next for melanoma therapy?CIViC databaseBRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionDifferential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanomaSurveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal GenomicsDetecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callersBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelIdentification of PLX4032-resistance mechanisms and implications for novel RAF inhibitorsA meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapyClinical development of dabrafenib in BRAF mutant melanoma and other malignancies.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Genotyping of cutaneous melanoma.The Molecular Taxonomy of Primary Prostate Cancer.Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaTumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testingClinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsCost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.Integrative molecular profiling of routine clinical prostate cancer specimens.Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma.MGDB: a comprehensive database of genes involved in melanoma.Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNAFast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMutERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanomaGenetics of melanomaA multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanomaRare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Development and clinical application of an integrative genomic approach to personalized cancer therapyAdvances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomesNext-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistanceTherapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Update on the targeted therapy of melanoma.Trametinib (GSK1120212) in the treatment of melanoma.
P2860
Q26770324-AFAC6FF7-F383-4550-80F1-60DFA7962E4FQ26865736-8640CF8D-0694-4626-B9AA-40FDAF33370AQ27006853-85B34816-10B5-47AB-8821-ADEF286BD084Q27612411-DBACA697-2892-47DF-9576-848C74DA0CB0Q27852730-099A029F-C89A-481B-90D4-2EACD485F92DQ28536351-E4CA2BE7-BE43-4731-954E-E8D3BFED0057Q28542977-F2A16CEF-1490-47CA-9AA3-DA4D98D34CCDQ30674708-DC4D3F80-B567-4BD4-8430-85E298C06E02Q33560928-7E4E291F-D98C-4CAD-8A9D-762C4B2D26A7Q33699641-ED354349-FA9C-42BA-8923-82FCFBDBBDEFQ33784436-2D55BF89-429D-4330-A8ED-2866C57B0870Q33875566-96438555-5C90-48A4-B2E7-4F36B2763CDBQ33977022-4EC82CE3-B597-4E39-A14A-EA3ABA2F2831Q34341465-858AFF3F-36F0-451E-B71A-44676125F840Q34550326-9DCCB521-A88D-435A-AA9E-B108D2174654Q34667738-E2854187-0029-4D3B-A64A-D0FBB67BCF96Q34674332-B79D408F-EC78-4E4D-AA02-2995FEC971F4Q34898560-EE2C193C-970B-4D43-8B05-8CBE16907A13Q34970350-E77E222E-89B7-4722-944E-1A73F80123FEQ35273776-7511E60B-566A-4DF9-95F2-A6A36E37EB44Q35534823-373C6C1E-0A64-4C83-88EB-ABB5107F917EQ35749307-FF560258-9891-49E1-B938-6CDE9B6106A5Q35820044-B7E7725F-D5EB-47BC-8CB5-3E63C76F894AQ35885523-E3AA6ECE-EB60-4B0B-988C-CC4890E14D62Q35892022-2FAB1917-6F29-4217-ACA8-039D495EBEDAQ35998474-172738B5-F887-4720-B897-513B84150C39Q36109610-80BB7757-4913-430B-8EA3-3303B93F9587Q36128449-54299FD7-9D74-47E2-A22F-579005B63E0BQ36265829-579CFAAA-7FF7-43D0-B5CA-6F07504B61E8Q36355962-0D1EB970-CDA0-4EA4-BA79-D3FE3E4B4140Q36563659-F355E253-4CAC-417B-A218-AE4D020A8E19Q36764374-7ED35E1E-366F-4E4B-94F3-A7F6B6BAFD25Q36896131-F537F2B2-DD85-42FF-A83A-D1D0B496EB0CQ36954557-D97C95E3-ECC4-4B34-89E0-7053677804DCQ37096363-88FFEEA0-53CA-425A-8068-4F622FD2D82BQ37138662-8E2144EC-BD8F-417D-9045-A450851B2F0AQ37632230-A7996051-CC56-4082-B3B4-D4DF0E393C6FQ38081987-8AA47C49-B819-464A-A0D7-C6B1155B3C91Q38082713-1DECC900-1E75-4FB2-8F10-DB3EF692A1BCQ38083794-F966718A-60A5-4CE4-9E9A-199773D3D90F
P2860
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@ast
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@en
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
@nl
type
label
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@ast
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@en
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
@nl
altLabel
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
@en
prefLabel
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@ast
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@en
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
@nl
P2093
P2860
P3181
P1433
P1476
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
@en
P2093
Charles Ng
Cindy L Vnencak-Jones
David B Solit
Donald Hucks
Donna J Hicks
James L Netterville
Jeffrey A Sosman
John A Glaspy
Junfeng Xia
Katherine Hutchinson
P2860
P3181
P356
10.1158/2159-8290.CD-12-0097
P577
2012-09-01T00:00:00Z